Janux Therapeutics (JANX) Return on Equity: 2021-2025
Historic Return on Equity for Janux Therapeutics (JANX) over the last 4 years, with Sep 2025 value amounting to -0.10%.
- Janux Therapeutics' Return on Equity fell 1.00% to -0.10% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.10%, marking a year-over-year decrease of 1.00%. This contributed to the annual value of -0.10% for FY2024, which is 7.00% up from last year.
- As of Q3 2025, Janux Therapeutics' Return on Equity stood at -0.10%, which was up 1.78% from -0.11% recorded in Q2 2025.
- In the past 5 years, Janux Therapeutics' Return on Equity ranged from a high of -0.05% in Q3 2021 and a low of -0.22% during Q2 2023.
- For the 3-year period, Janux Therapeutics' Return on Equity averaged around -0.13%, with its median value being -0.11% (2025).
- Per our database at Business Quant, Janux Therapeutics' Return on Equity fell by 12bps in 2022 and then increased by 15bps in 2024.
- Over the past 5 years, Janux Therapeutics' Return on Equity (Quarterly) stood at -0.09% in 2021, then dropped by 11bps to -0.19% in 2022, then rose by 3bps to -0.17% in 2023, then increased by 9bps to -0.08% in 2024, then fell by 1bps to -0.10% in 2025.
- Its Return on Equity stands at -0.10% for Q3 2025, versus -0.11% for Q2 2025 and -0.08% for Q1 2025.